RATIONALE: LAD2 human mast cells were developed over 15 years ago and have been distributed worldwide for studying proliferation, receptor expression, mediator release/inhibition and signaling. LAD2 cells were derived from CD34+ cells following marrow aspiration of a patient with aggressive mastocytosis. Another aspiration gave rise to the cell line LAD1 which has been under liquid N2 and not distributed due to the availability of LAD2. LAD1 cells were recently thawed for study. We queried whether LAD1 had unique properties for the study of human mast cell biology METHODS: LAD1 and LAD2 cells were cultured under identical conditions. Experiments examined proliferation, beta-hexosaminidase (beta-hex) release, surface receptor and granular protease expression, gene expression and infectivity with HIV. RESULTS: LAD1 cells were larger and more granulated as seen with Wright-Giemsa staining and FSC/SS expression, with cell numbers doubling in 4 wks, in contrast to LAD2 cells which doubled every 2 wks. Both LAD1 and LAD2 cells released beta-hex to an IgE-mediated stimulus. LAD1 cells showed log-fold increases in FcepsilonRI/CD117 and expressed CD133/CCR3(CD193)/ CCR5(CD195)/CXCR4(CD184) and IL3R(CD123). LAD2 expressed CD133/CD193 but not CD195/ CD184 or CD123. LAD1 tryptase expression was one log fold increased. Both cell lines could be infected with HIV. Expression arrays revealed differences in gene expression. CONCLUSIONS: LAD1 cells when compared to LAD2 cells have a slower proliferation rate, are larger and more granulated, have increased FepsilonRI/CD117 and tryptase expression and different gene expression. Thus, while LAD1 and LAD2 cells share many characteristics, in some situations, one cell line may have an advantage over the other.
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Concurrent mastocytosis and monoclonal gammopathy of undetermined significance, a case series Annely Richardson, MD, and Joseph H. Butterfield, MD FAAAAI; Mayo Clinic, Rochester, MN. RATIONALE: Systemic mastocytosis (SM) is a rare condition (1 case per 10,000 persons) characterized by increased mast cell presence in one or more body tissues. While SM-AHNMD has been associated with myeloid malignancies, SM has been inconsistently associated with plasma cell dyscrasias and even less so with monoclonal gammopathy of undetermined significance (MGUS). Here we report a potentially novel relationship between SM and MGUS in an eight-patient case series. METHODS: Eight cases with concurrent diagnoses of SM and MGUS are studied by chart review. Data examined include age of respective diagnoses, time between diagnoses, bone marrow biopsy results, Kit mutation analysis, and outcome. RESULTS: Eight cases with SM and MGUS were reviewed. Male-tofemale ratio was 1:1. Average age of diagnosis of SM was 45 years. Average age of diagnosis of MGUS was 51 years. All but one patient had elevated serum tryptase at presentation (the other had elevated urinary prostaglandin 11b-PGF2a). Mast cell bone marrow involvement was up to 20% in one case, and up to 10% in the remainder. Five of eight patients tested positive for the Asp816Val mutation. One patient with IgA kappa MGUS progressed to myelodysplasia, multilineage dysplasia and 20q abnormality. The other patients had monoclonal proteins involving IgG (three lambda, three kappa) and IgM (one lambda), none of which progressed. CONCLUSIONS: SM may be associated with subsequent MGUS. While the mean age of MGUS diagnosis is 70 years, our patients had an average age of 51 years at MGUS diagnosis, suggesting a potential earlier onset in those with SM. METHODS: Peripheral blood mononuclear cells (PBMCs) from 20 patients with indolent systemic mastocytosis (ISM) were analyzed to quantitate lymphocyte subpopulations by flow cytometry and correlated with clinical parameters of disease. DNA was extracted from patient PBMCs and analyzed to determine the allelic frequency of the mastocytosis-associated KITD816V mutation. RESULTS: The median frequency and absolute cell count of all lymphocyte subsets examined in this cohort were found to be within the normal range of healthy adult individuals. We then stratified the results according to clinical manifestations (autoimmunity, atopic disease, anaphylaxis, cancer, osteoporosis/osteopenia and chronic/recurrent infections) to determine if the lymphocytes subsets correlated any of these manifestations. We observed the median % (p50.032) and absolute count (p50.015) of CD19 + CD21 low CD38 low B cells were significantly higher in patients with a history of autoimmune disease. Counts of terminally differentiated CD4+ T cells were significantly higher in patients with osteoporosis (p50.038) or osteopenia (p50.045). CONCLUSIONS: Lymphocyte subsets in the peripheral blood of patients with ISM were in general not significantly different from those of the general population. Extensive lymphocyte phenotyping of PBMCs may, however, be able to help predict or monitor some specific clinical manifestations associated with ISM.
